354 related articles for article (PubMed ID: 30770859)
1. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.
van Andel H; Kocemba KA; Spaargaren M; Pals ST
Leukemia; 2019 May; 33(5):1063-1075. PubMed ID: 30770859
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.
Ren Z; van Andel H; de Lau W; Hartholt RB; Maurice MM; Clevers H; Kersten MJ; Spaargaren M; Pals ST
Blood; 2018 Mar; 131(9):982-994. PubMed ID: 29212806
[TBL] [Abstract][Full Text] [Related]
3. Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.
van Andel H; Ren Z; Koopmans I; Joosten SP; Kocemba KA; de Lau W; Kersten MJ; de Bruin AM; Guikema JE; Clevers H; Spaargaren M; Pals ST
Proc Natl Acad Sci U S A; 2017 Jan; 114(2):376-381. PubMed ID: 28028233
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma.
Chim CS; Pang R; Fung TK; Choi CL; Liang R
Leukemia; 2007 Dec; 21(12):2527-36. PubMed ID: 17882284
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.
Kocemba KA; Groen RW; van Andel H; Kersten MJ; Mahtouk K; Spaargaren M; Pals ST
PLoS One; 2012; 7(2):e30359. PubMed ID: 22363428
[TBL] [Abstract][Full Text] [Related]
6. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.
Spaan I; Raymakers RA; van de Stolpe A; Peperzak V
J Hematol Oncol; 2018 May; 11(1):67. PubMed ID: 29776381
[TBL] [Abstract][Full Text] [Related]
7. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma.
Kaur P; Mani S; Cros MP; Scoazec JY; Chemin I; Hainaut P; Herceg Z
Tumour Biol; 2012 Apr; 33(2):325-36. PubMed ID: 22351518
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway.
Xie Q; Chen L; Shan X; Shan X; Tang J; Zhou F; Chen Q; Quan H; Nie D; Zhang W; Huang AL; Tang N
Int J Cancer; 2014 Aug; 135(3):635-46. PubMed ID: 24374650
[TBL] [Abstract][Full Text] [Related]
10. Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease.
van Andel H; Kocemba KA; de Haan-Kramer A; Mellink CH; Piwowar M; Broijl A; van Duin M; Sonneveld P; Maurice MM; Kersten MJ; Spaargaren M; Pals ST
Oncogene; 2017 Apr; 36(15):2105-2115. PubMed ID: 27775078
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of SFRP5 promotes the metastasis and invasion of chondrosarcoma by expression inhibition and Wnt signaling pathway activation.
Sheng W; Zhang ZC; Shi DY; Wang BC; Wu Q; Shao ZW; Yang SH; He TC; Liu JX
Chem Biol Interact; 2018 Dec; 296():1-8. PubMed ID: 30125549
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma.
Narayanan BA; Doudican NA; Park J; Xu D; Narayanan NK; Dasgupta R; Mazumder A
Anticancer Res; 2012 Nov; 32(11):4697-707. PubMed ID: 23155232
[TBL] [Abstract][Full Text] [Related]
13. Protein arginine methyltransferase 5 (PRMT5) activates WNT/β-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Shailesh H; Siveen KS; Sif S
J Cell Mol Med; 2021 Feb; 25(3):1583-1600. PubMed ID: 33462997
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.
Jin Y; Xu L; Wu X; Feng J; Shu M; Gu H; Gao G; Zhang J; Dong B; Chen X
Oncol Res; 2019 Jun; 27(6):729-737. PubMed ID: 30837032
[TBL] [Abstract][Full Text] [Related]
15. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
16. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
[TBL] [Abstract][Full Text] [Related]
17. Anti-proliferative activity of CGK012 against multiple myeloma cells via Wnt/β-catenin signaling attenuation.
Choi PJ; O Y; Her JH; Yun E; Song GY; Oh S
Leuk Res; 2017 Sep; 60():103-108. PubMed ID: 28772205
[TBL] [Abstract][Full Text] [Related]
18. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases.
Boudin E; Fijalkowski I; Piters E; Van Hul W
Semin Arthritis Rheum; 2013 Oct; 43(2):220-40. PubMed ID: 23433961
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
20. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
